Zeo ScientifiX, Inc. 8-K

What Happened
Zeo ScientifiX, Inc. (ZEOX) filed a Form 8-K (Item 8.01) on January 7, 2026 reporting a joint press release announcing a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. The agreement is intended to advance and commercialize Cytora’s novel allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States. A copy of the press release is included as Exhibit 99.1 to the filing.

Key Details

• Announcement date: January 7, 2026 (reported on Form 8-K, Item 8.01).
• Partners: Zeo ScientifiX, Cytora Therapeutics Ltd. (clinical-stage biotech, Israel), and Made Scientific, Inc. (U.S.-based cell therapy CDMO).
• Program: Cytora’s allogeneic, off-the-shelf human oral mucosal stem cell therapy, targeted for advancement and commercialization in the U.S.
• Disclosure scope: The 8-K includes the press release as Exhibit 99.1; no financial terms, timelines, clinical milestones or regulatory details were disclosed in the filing.

Why It Matters
This filing signals a strategic shift or expansion for Zeo into a collaboration focused on cell therapy commercialization in the U.S., which could affect the company’s future product pipeline and commercial opportunities. Because the 8-K did not provide financial terms or development timelines, investors should watch for subsequent disclosures (e.g., future 8-Ks, 10-Q/10-K, or press releases) that provide details on costs, milestones, regulatory plans, and potential revenue impact.